Boehringer Ingelheim International has patented a method using SGLT-2 inhibitors like empagliflozin to treat oxidative stress, cardiovascular diseases, and metabolic disorders in patients with type 1 or type 2 diabetes. The method aims to reduce the risk of heart failure or hospitalization for heart failure in patients with a history of myocardial infarction. GlobalData’s report on Boehringer Ingelheim International gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Boehringer Ingelheim International, was a key innovation area identified from patents. Boehringer Ingelheim International's grant share as of February 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for using empagliflozin to reduce heart failure risk
A recently granted patent (Publication Number: US11918596B2) discloses a method for reducing the risk of heart failure or hospitalization for heart failure in patients with a previous or existing myocardial infarction. The method involves administering a therapeutically effective amount of empagliflozin, with options for dosage ranging from 10 mg to 25 mg, once daily. The treatment aims to reduce the risk of heart failure or hospitalization for heart failure in these patients, providing a potential preventive measure for individuals with a history of myocardial infarction.
Furthermore, the patent also covers a similar method for patients with a confirmed history of myocardial infarction, emphasizing the administration of empagliflozin once daily in either 10 mg or 25 mg doses. The goal remains consistent in both scenarios, focusing on reducing the risk of heart failure or hospitalization for heart failure in these specific patient populations. By outlining specific dosage regimens and treatment outcomes, this patent provides a structured approach to utilizing empagliflozin as a potential therapeutic intervention for individuals at risk of heart failure post-myocardial infarction.
To know more about GlobalData’s detailed insights on Boehringer Ingelheim International, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
